This demonstrates that the antitumor activity of LF is mostly due to its inhibitory effect on MEK–ERK signaling, and that inactivation of the p38 and JNK pathways is less relevant for tumor targeting and may cause dose-limiting toxicity. The gene discussed is MAP2K7; the disease is neoplasm.